A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

BioInnovation Institute Welcomes 12 New Companies to its Venture Lab Program

BioInnovation Institute

BioInnovation Institute (BII) is an international non-profit foundation incubating and accelerating world-class life science research.  Today they announced that twelve new companies have entered its Venture Lab acceleration program for early-stage companies. The cohort is strategically aligned with BII’s focus on supporting innovative early-stage start-ups that can improve human and planetary health.

The 12-month Venture Lab program is designed to support start-up companies with business acceleration, scientific, and team development, and provides a founder-friendly convertible loan of EUR 500,000 (approximately 4M DKK) plus access to labs and offices at the BII in Copenhagen. In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII’s Venture House program.

Bobby Soni, Chief Business Officer at BioInnovation Institute, said:

“Working across the planetary, therapeutics, women’s health, health tech and quantum industries, these twelve start-ups have demonstrated the drive and tenacity that align with BII’s mission in creating innovative solutions to address current challenges in these sectors. We once again look forward to supporting these start-ups in bringing their innovations into fruition by providing our knowledge, network, funding, and infrastructure to build successful companies.”

Support Provided to Each Start-Up

Each start-up will be supported in undertaking the necessary steps to reach initial proof-of-concept, to make a business plan and to set up a team. Assisted by a dedicated scientific advisor, a leadership coach and a BII business development expert, the new ventures will be guided in developing a detailed milestone plan and will be assisted in overcoming the challenges of growing a business allowing them to progress rapidly towards the market.

The new companies BII has accepted into the Venture Lab acceleration program are:

Planetary Health
  • CAMBIOTICS is developing precision probiotics for PFAS detoxification.
  • SNL Biosolutions has developed an innovative technology platform that can produce fermentation-based oils at scale and prevent deforestation. The technology can be used to produce a wide range of products spanning from food ingredients to sustainable aviation fuel.
  • SymbioMATCH produces effective biofertilizers tailored to each soil condition and legume crop.
  • PreTT is a pioneer in advancing pre-targeted radioimmunotherapies to improve the lives of millions of cancer patients.
  • Polyceutix is transforming cancer treatment by unleashing the full power of the immune system exactly where it is needed.
Women’s Health
  • Pharmista Technologies is developing a reusable pregnancy test which will be the start of a new generation of reusable diagnostics.
  • oasicare is on a mission to improve women’s health during childbirth and postpartum on a global scale. The Company’s first solution is a medical device preventing the risk of birth tears.
Health Tech
  • Zeta Diagnostics is developing a portable audio device that allows physicians to detect middle ear problems before they become permanent complications.
  • Glaze Life Sciences is developing a non-invasive device to measure blood glucose to improve the everyday life of people living with diabetes.
  • DiaSense is developing a quantum diamond-magnetic microscope to be used by neuroscientists to diagnose diseases and find cures.
  • Sqale is revolutionizing biomanufacturing by using quantum technologies.
  • Alea Quantum Technologies has developed a quantum random number generator that will enable safe and trusted data sharing in the post-quantum era.

Since its inception in 2018, BII has supported 100 start-ups and projects with EUR 89 million alongside the venture capital, industry and business expertise it provides to help them accelerate to the next level.  In total, BII’s start-ups have raised over EUR 428 million in external funding from both local and international investors.  Recent company successes include Embark LaboratoriesAdcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Cirqle Biomedical.


Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy